Anna Halpern, MD

Dr. Anna. B. Halpern is an Associate Professor in the Division of Hematology & Oncology at the University of Washington and an Assistant Professor in the Clinical Research Division at the Fred Hutchinson Cancer Center.  Her clinical focus is on myelodysplastic syndromes, myeloproliferative neoplasms and acute myeloid leukemia. She also does clinical and outcomes research in myeloid malignancies evaluating novel care strategies and therapeutic approaches.

Dr. Halpern completed undergraduate and medical school at Brown University in 2009, residency in Internal Medicine at the University of Chicago in 2013, and fellowship in Hematology-Oncology at the Fred Hutchinson Cancer Research Center/ University of Washington in 2017.

Financial relationships

Attribution:
Self
Type of financial relationship:
Other
Ineligible company:
Bayer
Topic:
research contract
Date added:
05/27/2022
Relationship end date:
08/31/2024
Attribution:
Self
Type of financial relationship:
Other
Ineligible company:
Jazz pharmaceuticals
Topic:
research contract
Date added:
05/27/2022
Relationship end date:
10/22/2026
Attribution:
Self
Type of financial relationship:
Other
Ineligible company:
Imago Biosciences
Topic:
research contract
Date added:
05/27/2022
Relationship end date:
08/31/2026
Attribution:
Self
Type of financial relationship:
Other
Ineligible company:
Gilead Sciences
Topic:
research contract
Date added:
05/27/2022
Relationship end date:
12/31/2024
Attribution:
Self
Type of financial relationship:
Other
Ineligible company:
Karyopharm Therapeutics
Topic:
research contract
Date added:
05/27/2022
Relationship end date:
10/31/2026
Attribution:
Self
Type of financial relationship:
Other
Ineligible company:
Incytes Pharmaceuticals
Topic:
research contract
Date added:
05/27/2022
Relationship end date:
12/31/2026
Attribution:
Self
Type of financial relationship:
Grant Or Contract
Ineligible company:
Merck
Topic:
research contract
Date added:
10/20/2023
Relationship end date:
08/31/2026
Attribution:
Self
Type of financial relationship:
Grant Or Contract
Ineligible company:
Disc Medicine
Topic:
research contract
Date added:
10/20/2023
Relationship end date:
12/30/2024
Attribution:
Self
Type of financial relationship:
Other
Ineligible company:
Abbvie
Topic:
consulting
Date added:
10/20/2023
Relationship end date:
08/30/2023

Return to Best of ASCO 2024, Seattle

Premier Hematology Oncology Conferences

Bookmark/Search this post

Anna Halpern, MD

Financial relationships

3380 146th PL SE, Suite 330	Bellevue, WA 98007	Phone - 425-6 16-0572
Visit our website to learn about our Global projects	Binaytara Foundation Cancer Center in Nepal

You are here

Anna Halpern, MD

Financial relationships